In an open-label study, six pediatric patients (age range, 3.5 weeks to 5.4 months) with
GER received metoclopramide 0.15 mg/kg oral solution every 6 hours for 10 doses. The
mean peak plasma concentration of metoclopramide after the tenth dose was 2-fold (56.8
μg/L) higher compared to that observed after the first dose (29 μg/L) indicating drug
accumulation with repeated dosing. After the tenth dose, the mean time to reach peak
concentrations (2.2 hr), half-life (4.1 hr), clearance (0.67 L/h/kg), and volume of
distribution (4.4 L/kg) of metoclopramide were similar to those observed after the first
dose. In the youngest patient (age, 3.5 weeks), metoclopramide half-life after the first and
the tenth dose (23.1 and 10.3 hr, respectively) was significantly longer compared to other
infants due to reduced clearance. This may be attributed to immature hepatic and renal
systems at birth.
Single intravenous doses of metoclopramide 0.22 to 0.46 mg/kg (mean, 0.35 mg/kg) were
administered over 5 minutes to 9 pediatric cancer patients receiving chemotherapy (mean
age, 11.7 years; range, 7 to 14 yr) for prophylaxis of cytotoxic-induced vomiting. The
metoclopramide plasma concentrations extrapolated to time zero ranged from 65 to 395
μg/L (mean, 152 μg/L). The mean elimination half-life, clearance, and volume of
distribution of metoclopramide were 4.4 hr (range, 1.7 to 8.3 hr), 0.56 L/h/kg (range, 0.12
to 1.20 L/h/kg), and 3.0 L/kg (range, 1.0 to 4.8 L/kg), respectively.
In another study, nine pediatric cancer patients (age range, 1 to 9 yr) received 4 to 5
intravenous infusions (over 30 minutes) of metoclopramide at a dose of 2 mg/kg to
control emesis. After the last dose, the peak serum concentrations of metoclopramide
ranged from 1060 to 5680 μg/L. The mean elimination half-life, clearance, and volume of
distribution of metoclopramide were 4.5 hr (range, 2.0 to 12.5 hr), 0.37 L/h/kg (range,
0.10 to 1.24 L/h/kg), and 1.93 L/kg (range, 0.95 to 5.50 L/kg), respectively.
INDICATIONS AND USAGE
The use of reglan
®
tablets is recommended for adults only. Therapy should not
exceed 12 weeks in duration.
Symptomatic Gastroesophageal Reflux
reglan
®
tablets are indicated as short-term (4 to 12 weeks) therapy for adults with
symptomatic, documented gastroesophageal reflux who fail to respond to conventional
therapy.
The principal effect of metoclopramide is on symptoms of postprandial and daytime
heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to
particular situations, such as following the evening meal, use of metoclopramide as single
doses prior to the provocative situation should be considered, rather than using the drug
throughout the day. Healing of esophageal ulcers and erosions has been endoscopically
demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. As there is no
documented correlation between symptoms and healing of esophageal lesions, patients
with documented lesions should be monitored endoscopically.
Diabetic Gastroparesis (Diabetic Gastric Stasis)
reglan
®
tablets (metoclopramide tablets, USP) is indicated for the relief of symptoms
associated with acute and recurrent diabetic gastric stasis. The usual manifestations of
Reference ID: 3018416